China Oncology Clinical Trials Market Report 2022 to 2030

China Oncology Clinical Trials Market Analysis

$ 3999

China's oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the country and efforts to promote research, collaboration, and innovation. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Jiangsu Hengrui Pharmaceutical & Sino Biopharmaceutical.

ID: IN10CNCT006 CATEGORY: Clinical Trials GEOGRAPHY: China AUTHOR: Vidhi Upadhyay

Buy Now

China Oncology Clinical Trials Market Executive Summary

The China oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. China is the world's second-largest pharmaceutical market, with a significant middle-class population and rising disposable income, and it will continue to increase fast in the future years. Western commercial enterprises' engagement in trials conducted in China has progressively increased over the last decade, from approximately 100 trials per year in 2010 to over 350 in 2021. China estimated 4,820,000 new cancer cases and 3,210,000 cancer deaths in 2022. Lung cancer is the most frequent cancer in China followed by colorectum, stomach, liver, and breast.

There is a surge in the number of immunotherapy medications under development in China. In August 2021, China approved the fifth and sixth locally produced PD-1/PD-L1 inhibitors. Domestic Chinese studies often involve solely individuals from the local Chinese community, and regulatory bodies outside of China are likely to want more diversified patient data before contemplating permission. With this in mind, we may expect to see an increasing number of Chinese sponsors either conducting their own multi-regional clinical trials (MRCTs) or collaborating with Western corporations to conduct global studies.

Some of the centers performing oncology trials in China are;

Peking University Cancer Hospital
Shanghai Cancer Center
Fudan University Shanghai Cancer Center
Sun Yat-Sen University Cancer Center
Beijing Cancer Hospital
Chinese Academy of Medical Sciences Cancer Hospital

china oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Lung cancer is the most often diagnosed cancer in China, with a big patient population. This implies that a high number of people are eligible to participate in clinical trials, notably for lung cancer and other prevalent malignancies. In recent years, China has made major efforts in developing its clinical research infrastructure. The government has created a number of national and regional clinical research facilities, as well as a rising number of contract research organizations (CROs) that provide a variety of clinical trial services. These expenditures have contributed to the enhancement of the quality and efficiency of cancer clinical trials in China.

Market Restraints

There are also certain limitations in performing cancer clinical trials in China. The regulatory climate is one of the most significant challenges. The regulatory structure in China for clinical trials is complicated, making it difficult for international businesses to navigate. As a result, several businesses have partnered with local CROs or formed joint ventures with Chinese enterprises to perform clinical studies in the nation. Another difficulty is the linguistic barrier. Although English is widely spoken in China's clinical research community, there are certain linguistic and cultural distinctions that might provide communication issues for international organizations and researchers.

Competitive Landscape

Key Players

Novartis AG
Roche Holding AG
AstraZeneca
Merck & Co., Inc.
Jiangsu Hengrui Pharmaceutical (CHN)
Sino Biopharmaceutical (CHN)
CSPC Pharmaceutical (CHN)
Qilu Pharmaceutical Co., Ltd. (CHN)

Notable Insights

December 2021, BeiGene and Novartis Extend Partnership to Research and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Cancer Treatments Are Available in Major Chinese Markets.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.